China Biotech Services Holdings Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was HKD 588.84 million compared to HKD 131.24 million a year ago. Net income was HKD 165.95 million compared to HKD 19.89 million a year ago. Basic earnings per share from continuing operations was HKD 0.095 compared to HKD 0.003 a year ago.
For the nine months, sales was HKD 1,275.75 million compared to HKD 505.4 million a year ago. Net income was HKD 304.09 million compared to HKD 104.64 million a year ago. Basic earnings per share from continuing operations was HKD 0.166 compared to HKD 0.028 a year ago.